Pivitol Study of ENBREL in Rheumatoid Arthritis Patients Established Foundation for FDA Approval
Who: Immunex Corporation (NSQD:IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE:AHP), announce the publication of Phase III data for ENBREL (etanercept) for the treatment of rheumatoid arthritis (RA) in the Annals of Internal Medicine.
What: The six month study is based on 234 patients with active rheumatoid arthritis with inadequate response to DMARDs.
Date of Publication: March 16, 1999
Spokespeople: Study investigators, company spokespersons and patients on ENBREL are available for interviews
Contact:
Shari Beagelman 212-614-4673; Shari_beagelman@bm.com
Nicole Preiss 212-614-5237; Nicole_preiss@bm.com
Background: ENBREL was approved November 2, 1998 by the U.S. Food and Drug Administration as a treatment for moderately to severely active RA in patients who have an inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs).
Annals of Internal Medicine